Carnival and Other Cruise Lines Get A Delayed Opening and AstraZeneca Made A Fatal Mistake
Carnival Cruise Line is an international cruise line that has gone through many controversies and was one of the hardest-hit stocks at the start of the COVID-19 pandemic last year. Recently Carnival has made a strong recovery, climbing from below $8 a share to over $25 in the span of a year.
Most recently, was taken a hit once more, granted much smaller than before, because the Centers for Disease Control and Prevention (CDC) said the current ban on U.S. cruises will remain until Nov. 1. With so many expecting a faster reopening considering the increasing number of vaccinations, this news took a toll.
The news didn’t just affect Carnival – down 1.7%; Royal Caribbean at $83.25 is down 0.8%, and Norwegian at $25.97 is down 2.4% for the day.
Despite an impressively quick vaccine, delivered in just about 9 months, AstraZeneca has had its share of hurdles. The latest of which concerns the very achievement boosting the stock, the vaccine. Recently, AstraZeneca has accidentally provided a half dose of the vaccine during clinical trials, creating a negative media reaction, with many criticizing AstraZeneca for omitting crucial information from its public statements.
On top of this, many have questioned whether the vaccine’s data is truly accurate. In Europe, this has caused a political conundrum among leaders. All in all, the company is keeping pace with competitors: shares are down around 2% since January, similarly, Pfizer’s stock has also moved down since January.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.